Researchers at Renal Week 2010 in Denver have reported on what they believe is the first prospective, randomized study to show that targeting a serum hemoglobin (Hb) level of 13 g/dL or higher has a renoprotective effect in kidney transplant patients.
A significant proportion of patients with CKD but not on dialysis (CKD-NOD) with new-onset moderately severe anemia do not receive treatment with iron or erythropoiesis-stimulating agents (ESAs), suggest study findings presented at Renal Week 2010 in Denver.
Angiotensin receptor blocker (ARB) treatment may affect response to erythropoiesis-stimulating agents (ESAs) in hemodialysis (HD) patients by disturbing iron homeostasis, Japanese researchers reported at Renal Week 2010 in Denver.
High and low transferrin saturation (TSAT) levels contribute independently to increased mortality among individuals with normal and reduced kidney function in the general U.S. population, according to researchers who presented their study at Renal Week 2010 in Denver.
Patients with end-stage renal disease who receive predialysis intravenous iron therapy are more likely to start hemodialysis with higher hemoglobin (Hb) levels and to achieve better Hb control better compared with patients treated with oral iron prior to dialysis initiation, French researchers reported at Renal Week 2010 in Denver.
Hemodialysis (HD) patients may be receiving excessive intravenous (IV) iron that could contribute to iron overload and toxicity in the long term, suggest new data presented at Renal Week 2010 in Denver.
Blood transfusions increase the risk of adverse graft and patient outcomes in anemic renal transplant recipients, but treatment with erythropoiesis-stimulating agents (ESAs) do not, according to a study presented at Renal Week 2010 in Denver.
Changes in interdialytic weight are associated with reciprocal changes in both serum hemoglobin (Hb) and, consequently, doses of erythropoietin-stimulating agents (ESAs), according to researchers who presented a study at Renal Week 2010 in Denver.